Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24444132 | 0.70 | CYP1A2 (0.46) | SLC29A1CYP1A2 | |
| SCHEMBL24258630 | 0.70 | CYP1A2 (0.46) | SLC29A1CYP1A2 | |
| SCHEMBL24258662 | 0.70 | SLC29A1 (0.40) | SLC29A1 | |
| SCHEMBL21263864 | 0.70 | SLC29A1 (0.56) | SLC29A1 | |
| SCHEMBL24258589 | 0.68 | SLC29A1 (0.39) | SLC29A1 | |
| SCHEMBL21264012 | 0.67 | SLC29A1 (0.46) | SLC29A1CYP1A2POLA1 | |
| SCHEMBL25688724 | 0.66 | SLC29A1 (0.49) | SLC29A1 | |
| SCHEMBL20908785 | 0.66 | CYP1A2 (0.38) | CYP1A2ADORA2AADORA3POLA1ADORA2B | |
| SCHEMBL25688725 | 0.63 | SLC29A1 (0.39) | SLC29A1 | |
| SCHEMBL24322061 | 0.62 | POLA1 (0.32) | ADORA2AADORA3POLA1ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | SLC29A1 367/4885CYP1A2 2862/4885ADORA2A 1110/4885 |
| US-20220117995-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, DUT | SLC29A1 367/4885CYP1A2 2862/4885ADORA2A 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.